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ABSTRACT
Background
This evaluation was based at Mosta Health Centre with a 
particular focus on the blood investigation results clinic. 
Objectives
To get a clinical profile of the patients being seen at the 
clinic, to assess whether risk assessment tools are being 
used in the management of dyslipidaemia and to evaluate 
patient feedback about the clinic.
Method
This consisted of a cross-sectional observational study 
carried out over a five-week period between the end 
of October and the end of November 2017. Data was 
collected retrospectively immediately after completion 
of the clinic on three random days every week. Data 
collection was divided into two lists of patients – those 
who attended and those who failed to attend their 
appointment. A patient questionnaire was also handed to 
patients to fill in after attending their appointment. Data 
was inputted in Excel 2010 and analysed using Statistical 
Package for Social Sciences (SPSS) 22.
Results
A total of 181 patients had a registered appointment at 
the blood investigation results clinic during the period 
of data collection. Seventy-five per cent of these patients 
attended for their appointment, with 62.2% being 
females. Routine blood investigations were taken in 
80.7% of patients, thyroid function tests in 71.9% and 
glycosylated haemoglobin in 31.9%. Fourteen point eight 
per cent of patients had tumour markers booked, and 
a significant association was found between gender and 
whether tumour markers were ordered. A risk assessment 
tool was used in only 21% of the patients seen at the 
clinic for a lipid profile result, with the majority of General 
Practitioners (GPs) using the QRISK®2 cardiovascular 
disease calculator. Seventy eight patient satisfaction 
questionnaires were filled in during the period of data 
collection, and the percentage of patients who gave a 
very positive response (>8) for questions 1, 2 and 3 was 
92%, 89% and 97% respectively. 
Conclusion
Patient attendance at the blood investigation results clinic 
at Mosta Health Centre during the period under review 
was reasonably good, and patients were overall satisfied 
by the service provided. Tumour markers were found to 
be ordered more frequently in male patients, due to the 
common request for the PSA test. Risk assessment tools 
were used by GPs in only 14% of the total number of 
patients seen at the clinic, and the QRISK®2 cardiovascular 
disease calculator was the most commonly used tool.
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INTRODUCTION
Mosta Health Centre is one of the eight health centres 
which are the core of the primary health care service 
provided by the Government in Malta (Primary Health 
Care Department, 2017). One of the services offered 
on an almost daily basis is blood-letting, with patients 
being referred from their private General Practitioner 
(GP), the GP at the health centre, diabetic clinic in 
primary or secondary care, or several outpatient clinics 
at Mater Dei Hospital. Approximately 450 patients 
make use of the blood-letting service at Mosta Health 
Centre on a weekly basis (data from Clinical Patient 
Administration System (CPAS), January 2018). The 
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Blood Investigation Results clinic was re-introduced 
in October 2017 at Mosta Health Centre with the aim 
of providing follow-up to patients who do not have a 
private GP or outpatient follow-up appointment.
The clinic is run by General Practitioners on weekdays 
between 11am and 1pm. Ten minute appointment 
slots are available, and after blood-letting patients are 
instructed by nurses or receptionists whether they 
require an appointment to be given the results. During 
the appointment, results are reviewed and discussed with 
the patients. Any medication modifications or additions 
are made, and the necessary examination, prescriptions, 
referrals or follow-up investigations are organized as 
required by the individual patient. 
Objectives
The objectives of this evaluation were: 
1. To get a clinical profile (specifically the demographic 
factors, presence or absence of any medical conditions 
and type of investigations ordered) of the patients 
being seen at the Blood Investigation Results clinic;
2. To assess whether risk assessment tools are being 
used in the management of dyslipidaemia;
3. To evaluate patient feedback about the clinic (through 
a short questionnaire).
METHOD
Data collection
This consisted of a cross-sectional observational study. A 
data collection form was designed on Microsoft Excel to 
facilitate data collection. Data was collected over a five-
week period between the end of October and the end 
of November 2017. Data was collected retrospectively 
immediately after completion of the clinic on three random 
days every week, and the list of patients, their record 
files and relevant investigations carried out through the 
Information Clinical Manager (ICM) system were reviewed. 
Such immediate collection of data allowed thoroughness 
of collection and minimised errors. Data collection was 
divided into two lists of patients – those who attended and 
those who failed to attend their appointment.
After due discussion amongst the authors and based 
on the aims of the study, it was decided that data collected 
should include:
•	 Age,	gender	and	locality
•	 Presence	or	absence	of	any	medical	conditions
•	 Types	of	blood	investigations	ordered
•	 Any	other	investigations,	including	urine	tests,	bone	
density and ECG
•	 Values	of	total	cholesterol,	triglycerides,	low-density	
lipoprotein (LDL) and high-density lipoprotein 
(HDL), fasting blood glucose (FBG), haemoglobin, 
glycosylated haemoglobin (HbA1c)
•	 Presence	of	a	previously	deranged	lipid	profile
•	 Whether	 a	 risk	 assessment	 tool	was	used	 in	 the	
assessment of dyslipidaemia and the risk level if 
this was used
•	 Whether	 the	 patient	was	 already	 on	 a	 statin,	 or	
whether a statin was started on the day of the 
appointment
A patient questionnaire was also prepared, and 
this was handed to patients by the receptionist on 
arrival. Prior to distributing the questionnaire to 
the patients, the questions were reviewed by all 
four authors for validity and reliability. Patients 
were instructed to fill in the questionnaire after 
their appointment and deposit the completed 
questionnaire in a sealed box that was available at the 
reception. The questionnaire was available in Maltese 
and English and consisted of three questions, with 
a 0 to 10 rating scale as a response (See Appendix). 
Space was also provided for anyone who wished to 
add any comments or suggestions.
Data analysis
Data input and analysis was carried out using Microsoft 
Excel. Further analysis was conducted using Statistical 
Package for Social Sciences (SPSS) programme version 22. 
Study approval
This evaluation was approved by the Department of 
Primary Health Care and by the Data Protection officer 
of the Department. 
Standards
The NICE Guideline ‘Lipid modification: cardiovascular risk 
assessment and the modification of blood lipids for the primary 
and secondary prevention of cardiovascular disease’ was used 
as a guide for the use of risk assessment tools, as well 
as the management of dyslipidaemia and recommended 
follow-up after starting treatment (National Institute for 
Health and Care Excellence, 2014).
RESULTS
Attendance at clinic
During the five weeks under review, 181 patients had 
a registered appointment at the Blood Investigation 
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Results clinic during the particular days that data was 
being collected. Of these patients 61.9% were females 
and 38.1% were males. Forty-six patients (25%) failed 
to attend their appointment.
Demographic details 
Sixty-two point two per cent (84) of the patients who 
attended their appointment were females and 37.8% (51) 
were males. The age/sex distribution of these patients is 
reproduced in Figure 1.
Forty per cent of the patients who attended their 
appointment resided in Mosta, with 28.1% coming from 
St Paul’s Bay (SPB) and 16.3% from Naxxar. A summary 
of the number of patients who attended according to 
locality can be seen in Figure 2.
Of the 25% who failed to attend their appointment, 
60.9% were females, and the most were aged 60-69 years. 
No significant association was found between defaulters 
and increasing distance of resident locality from the 
clinic, with the majority of patients residing in Mosta.
Medical conditions
The presence or absence of any medical condition in 
patients who had a registered appointment with the clinic 
was also recorded. These conditions include hypertension, 
asthma, ischaemic heart disease, chronic kidney disease, 
liver disease, diabetes and inflammatory bowel disease. 
This data was collected from the patient files in the case of 
patients who failed to attend their appointment, and from 
record files as well as information given by the patients 
themselves who attended the clinic appointment.
Sixty-one per cent of the patients who attended their 
appointment had a significant past medical history, while 
medical conditions were present in 48% of the patients 
who did not attend.
Investigations
Eighty point seven per cent of the patients who attended 
their appointment had ‘routine blood investigations’ 
taken (complete blood count, renal profile, lipid 
profile, liver profile and fasting blood glucose), 71.9% 
had thyroid function tests and 31.9% were tested for 
glycosylated haemoglobin (HbA1c).
Forty point seven per cent of the patients seen at the 
clinic had a previously deranged lipid profile (elevated 
total cholesterol).
Figure 1: Age/sex distribution of patients who attended their appointment
Figure 2: Distribution by locality of patients who attended
their appointment
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Fourteen point eight per cent of patients had tumour 
markers booked (these included Prostate-Specific Antigen 
(PSA), cancer antigen 19-9 (Ca19.9), carcinoembryonic 
antigen (CEA) and cancer antigen 25 (CA-125)). A 
significant association (p<0.05) was found between sex 
and whether tumour markers were ordered, with males 
having tumour markers ordered more frequently.
Three point seven per cent of the patients who 
attended the clinic had no blood investigations 
booked, and presented for results of bone density, 
ECG or urine tests.
A summary of the percentage of all investigations taken 
in patients who attended the clinic is illustrated in Figure 3.
Table 1 shows the minimum and maximum values, 
and the mean with 95% confidence intervals, for a 
number of individual blood investigation parameters 
of the patients seen at the clinic, namely total 
cholesterol, HDL, LDL, total cholesterol:HDL ratio, 
fasting blood glucose, creatinine, haemoglobin and 
glycosylated haemoglobin.
Forty-one point three per cent of the non-attenders 
had a previously deranged lipid profile (elevated total 
cholesterol), which was similar to that of patients who 
attended for their appointment.
Use of risk assessment tools 
and management of dyslipidaemia 
A risk assessment tool was used in only 21% of the 
number of patients seen at the clinic who came for a 
lipid profile result. General Practitioners made use of 
the QRISK®2 cardiovascular disease calculator in 79% 
of these cases, with the remaining 21% having the 
Framingham risk score used.
Of the patients in which a risk assessment tool was 
used, 58% had a risk level classified as ‘High’. Of these, 
18% were already taking a statin, 36% were started on 
a statin and 45% were not started on a statin. All the 
patients who were started on a statin had repeat lipid 
profile and liver function tests booked as a follow-up in 
three months’ time.
Figure 3: Percentage of investigations ordered in patients who attended their appointment
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Figure 4: Summary of the use of risk assessment tools at the blood investigation
From the 86% of patients in whom a risk assessment 
tool was not used, 37% did not have a lipid profile 
included with their investigations and 28% had total 
cholesterol level less than 5mmol/L. Thirty-five per cent 
had a total cholesterol level more than 5mmol/L, and 
41% of these were already on a statin. 
A summary of the above results is illustrated in a flow 
chart in Figure 4. 
Patient Satisfaction Questionnaire
Over the period of data collection, a total of 78 
questionnaires were filled in, which is 57.8% of the 
total number of patients who attended. Two of the 
questionnaires were incompletely filled and excluded 
from the data analysis. Hence the total amount of 
questionnaires included in the analysis was 76. Question 
1 which focused on the care received from the doctor 
was given a maximum score of 10 and a minimum 
score of 6 (mean value = 9.45 [95% CI: 9.23-9.67]). 
Question 2 dealt with the amount of time dedicated for 
the appointment and was given a maximum score of 10 
and a minimum score of 4 (mean value = 9.21 [95% CI: 
8.86-9.56]). Question 3 asked how likely it is that another 
appointment would be fixed with this clinic by the patient 
and was given a maximum score of 10 and a minimum 
score of 6 (mean value = 9.59 [95% CI: 9.40-9.79]).
The percentage of patients who gave a very positive 
response (>8) for questions 1, 2 and 3 was 92%, 89% 
and 97% respectively.
A few examples of the comments left by patients 
include the following: 
•	 “The	appointment	 is	 good	 so	 that	we	can	ask	 the	
doctor any questions we need to know, and it saves 
time. Thank you.”
•	 “It-tabib	 kien	ġentili ħafna u anke tani kopja tar- 
riżultat biex inżommu. Grazzi ħafna u prosit. Keep 
it up.” [“The doctor was very considerate and even 
gave me a copy of the results to keep. Many thanks 
and well done. Keep it up.”]
•	 “I	think	the	whole	clinic	has	improved	in	its	service	
- even though there has been an influx of patients 
using it. Thank you.” 
DISCUSSION
Over the five-week period under review, between the end 
of October and the end of November 2017, there was 
reasonably good attendance at the Blood Investigation 
Results clinic, with 75% of patients who had a registered 
appointment attending the clinic. Possible reasons for 
patient non-attendance include patients who have pending 
appointments at the Diabetic Clinic (Mosta Health Centre/
Mater Dei Hospital) or the Outpatient Department at Mater 
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Dei Hospital, patients who would have visited the GP clinic 
prior to their appointment and would have possibly been 
given the results during that visit, and patients having 
double appointments registered on the system. 
Most of the patients attending the blood investigation 
results clinic were aged more than 60 years. The fact 
that the clinic takes place in the morning might make 
it difficult for people who work during office hours to 
attend at this time. A similar appointment system in the 
evening might be more attractive and practical for the 
younger working population. 
Tumour markers were found to be ordered more 
frequently in male patients, with the likely reason 
being the frequent request for PSA in males. Tumour 
markers have a limited role in general practice, and the 
routine ordering of such investigations as a screening 
tool in asymptomatic patients is not recommended. 
Tumour markers have low sensitivity and specificity, 
and the inappropriate ordering of such tests can lead to 
false reassurance if the result is negative or a series of 
unnecessary investigations if the result is positive.
Possible reasons for the use of tumour markers 
in primary care may include requests by patients 
themselves to order these markers - possibly resulting 
from misinformation on the media, lack of patient 
education and fear of having cancer, as well as the fact that 
other investigations such as ultrasound scans cannot be 
ordered directly by general practitioners. Tumour markers 
have been mainly recommended in assessing response 
to treatment and detecting recurrence in known cases of 
malignancy (National Cancer Institute, 2018). Even in 
the case of PSA, which is used very commonly to screen 
males for prostate cancer, an increased level can be due to 
benign conditions and most males with a high PSA level 
do not have prostate cancer (National Cancer Institute, 
2018). Patients should be given enough information to 
be able to make an informed decision about whether 
a PSA test should be taken or not (Leyva et al., 2016).
A risk assessment tool was used in only 21% of 
the patients seen at the clinic who came for a lipid 
profile result, with the majority having the QRISK®2 
cardiovascular disease calculator used.
QRISK®2 is a prediction algorithm for cardiovascular 
disease (CVD) originally developed by Hippisley-Cox 
and published in the BMJ in 2008 (Hippisley Cox et al., 
2008). It uses traditional risk factors (age, blood pressure, 
smoking status and ratio of total serum cholesterol to 
high-density lipoprotein cholesterol) together with body 
mass index, ethnicity, family history, chronic kidney 
disease, rheumatoid arthritis, atrial fibrillation, diabetes 
mellitus and antihypertensive treatment. The QRISK®2 
cardiovascular disease calculator can easily be accessed 
from https://www.qrisk.org/.
The NICE lipid-modification guidelines recommend 
the use of the QRISK®2 cardiovascular risk assessment 
tool for primary prevention in people aged less than 
84 years (including type 2 diabetics), as opposed to 
previous guidance offering a choice between QRISK®2 
and Framingham-based assessment tools (National 
Institute for Health and Care Excellence, 2014). This 
guideline also recommends that the threshold for 
consideration of treatment with statins is a risk of CVD 
events of more than 10% over 10 years. Atorvastatin 
20mg daily is recommended first-line, which is a change 
from simvastatin 40 mg daily recommended in previous 
guidelines. Locally, simvastatin still tends to be the initial 
choice, possibly due to Government of Malta Schedule 
V protocol 12 which states that patients are entitled 
Table 1: Summary of results for individual blood investigation parameters
Minimum Maximum Mean
95% Confidence Interval of the Difference
Lower Upper
Total Cholesterol 3.02 7.50 5.24 4.98 5.39
HDL 0.74 2.88 1.61 1.50 1.69
LDL 1.30 4.88 3.01 2.81 3.14
Total: HDL ratio 1.28 9.00 3.47 3.19 3.68
FBG 4.33 11.37 5.75 5.50 6.00
Creatinine 41.00 148.00 75.66 70.61 79.19
Haemoglobin 11.30 18.20 14.33 14.06 14.60
HbA1c 4.70 8.80 5.89 5.63 6.16
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to atorvastatin when despite the use of another statin 
(simvastatin/fluvastatin), the respective target LDL levels 
(as per protocol) have not been achieved (Department of 
Health Malta, 2012).
In this study, 45% of the patients with a high risk 
level were not started on a statin. Possible reasons for 
this include patient reluctance to start treatment, patients 
opting for a trial of dietary and exercise changes and 
repeat lipid profile, contraindications or previous side-
effects with statins, or failure of the GP to offer statins 
as part of the management plan.
NICE Guidelines also recommend measuring total 
cholesterol and HDL-cholesterol after 3 months of 
treatment, with the aim of a 40% reduction in non-HDL 
cholesterol. All the patients started on a statin at the 
Blood Investigation Results clinic during this study had 
follow-up blood investigations booked. Creatine kinase 
(CK) should not be routinely measured in asymptomatic 
people on statins or before starting statins; it should only 
be taken prior to starting treatment in people who have 
had persistent generalised unexplained muscle pain (with 
or without lipid-lowering therapy), and statins should not 
be initiated if CK levels are more than 5 times the upper 
limit of normal, in 2 tests 7 days apart (National Institute 
for Health and Care Excellence, 2014).
The results of the Patient Satisfaction Questionnaires 
reflect an overall appreciation of the Blood Investigation 
Results clinic based on an appointment system. The 
vast majority of patients who were seen at the clinic 
were satisfied by the service provided, considered the 
amount of time dedicated to them satisfactory and are 
willing to continue using the service in the future. This is 
supported by positive comments left by several patients 
who consider this system as convenient and time saving. 
A factor frequently pointed out in the comments section 
was the importance of short waiting times.
Strengths and limitations
Over the five-week period under review, data of 72% of 
the total registered patient appointments during that 
period was recorded. Therefore, the sample of data is very 
much reflective of the activity at the Blood Investigation 
Results clinic over this period of time.
A possible limitation of this study is that there were 
a few occasions when one of the authors was assigned 
to the blood investigation results clinic on the day of 
data collection, and this may have been a source of bias 
with regards to the use of the risk assessment tools in 
the management of dyslipidaemia.
The specific medical conditions for each patient 
were not recorded in this study, and only the presence 
or absence of these was recorded. This was therefore 
a limiting factor particularly in evaluating the clinical 
profile of the patients that were being seen at the clinic.
Another limitation of the study was that patient 
satisfaction questionnaires were not always distributed 
to patients by the receptionist, as well as patient illiteracy 
making them unable to complete the questionnaire. 
RECOMMENDATIONS
The NICE Guideline ‘Lipid modification: cardiovascular 
risk assessment and the modification of blood lipids for 
the primary and secondary prevention of cardiovascular 
disease’ or a summary of this guideline should be 
forwarded to GPs by email, particularly highlighting 
the section regarding use of the risk assessment tools, 
initiation of statins and recommended follow-up 
thereafter. This would serve as a reminder about the 
usefulness of using this tool in everyday practice and 
the resulting improved patient care. A small poster 
about the use of the QRISK®2 cardiovascular disease 
calculator in the all the GP rooms will serve as a 
reminder for all doctors. A refresher lecture for GPs 
and GP trainees focusing on this topic would also be 
useful. Developing a local protocol for the management 
of dyslipidaemia in primary care would help to provide 
evidence-based guidance to GPs and result in more 
standardized patient management. A re-evaluation of 
the use of risk assessment tools in the management of 
dyslipidaemia can be undertaken after these guidelines 
have been distributed.
Guidelines should be issued for reception staff and 
doctors/nurses at Mosta Health Centre stating the purpose 
of the Blood Investigation Results clinic and when an 
appointment should be arranged. Automatically registering 
patients for a results appointment after having blood 
tests taken should be avoided and the purpose of the 
appointment should be explained to patients. Advising 
patients to cancel appointments in advance if they cannot 
make it should be encouraged, as this affects the waiting list 
for appointments at the blood investigation results clinic.
Further evaluation of the clinic, including the 
source of referral for blood investigations, the reason/s 
for ordering the blood tests (with a particular focus on 
certain investigations, such as tumour markers) and the 
length of time the patients have to wait between taking 
blood tests and getting an appointment for the results, 
should be considered. 
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Based on the good patient feedback received, 
consideration should also be given to arranging 
appointments for results of investigations other than 
blood tests, like for example bone mineral density results.
CONCLUSION
Patient attendance at the blood investigation results 
clinic at Mosta Health Centre during the period under 
review was reasonably good, and patients were overall 
satisfied by the service provided. Tumour markers were 
found to be ordered more frequently in male patients, 
due to the common request for the PSA test. Risk 
assessment tools were used by GPs in only 21% of 
the patients seen at the clinic for a lipid profile result, 
and the QRISK®2 cardiovascular disease calculator 
was the most commonly used tool. A refresher 
lecture about or distribution of the NICE Guideline 
‘Lipid modification: cardiovascular risk assessment and the 
modification of blood lipids for the primary and secondary 
prevention of cardiovascular disease’ to GPs would be 
useful as a reminder about the benefit of using this 
tool in everyday clinical practice.
Appendix
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